310 related articles for article (PubMed ID: 395097)
1. The effect of three days of blood glucose normalization by means of an "artificial endocrine pancreas" on the concentrations of growth hormone, glucagon, and cortisol in juvenile diabetics.
Schock A; Schultz M; Kerner W; Maier V; Pfeiffer EF
Horm Metab Res Suppl; 1979; (8):93-6. PubMed ID: 395097
[TBL] [Abstract][Full Text] [Related]
2. D-Trp8-D-Cys14-somatostatin--demonstration of its differential suppressive activity in juvenile diabetics.
Neuhaus C; Kerner W; Maier V; Pfeiffer EF
Horm Metab Res Suppl; 1979; (8):115-8. PubMed ID: 395066
[TBL] [Abstract][Full Text] [Related]
3. Assessment of daily insulin requirements in diabetics with an artificial endocrine pancreas.
Lambert AE; Buysschaert M; Lambotte L
Horm Metab Res Suppl; 1979; (8):120-7. PubMed ID: 395067
[No Abstract] [Full Text] [Related]
4. The external artificial pancreas: an instrument to induce remissions in severe recent juvenile diabetes. Comparison with a preprogrammed insulin infusion system.
Mirouze J; Selam JL; Pham TC; Orsetti A
Horm Metab Res Suppl; 1979; (8):141-5. PubMed ID: 395071
[TBL] [Abstract][Full Text] [Related]
5. Circadian variation of insulin requirement in insulin dependent diabetes mellitus the relationship between circadian change in insulin demand and diurnal patterns of growth hormone, cortisol and glucagon during euglycemia.
Trümper BG; Reschke K; Molling J
Horm Metab Res; 1995 Mar; 27(3):141-7. PubMed ID: 7607604
[TBL] [Abstract][Full Text] [Related]
6. Influence of cortisol circadian variations on insulin need and delivery in insulin-dependent diabetics. Assessment by the artificial beta cell.
Altomare E; Moulin JP; Tavares S; Bourelly N; Lassmann V; Vague P
Horm Metab Res Suppl; 1979; (8):110-5. PubMed ID: 395065
[No Abstract] [Full Text] [Related]
7. Insulin treatment and state of control before, during, and after connection to a glucose controlled insulin infusion system (Biostator).
Christiansen JS; Svendsen PA; Deckert T
Horm Metab Res Suppl; 1979; (8):131-4. PubMed ID: 395069
[TBL] [Abstract][Full Text] [Related]
8. [Artificial pancreas: clinical and therapeutic value in 11 patients (author's transl)].
Buysschaert M; Lambotte L; Lambert AE
Nouv Presse Med; 1979 Jul 14-28; 8(32):2597-601. PubMed ID: 386266
[TBL] [Abstract][Full Text] [Related]
9. Variation induced by a three-days application of the artificial beta-cell on glucagon, growth hormone and catecholamine secretion, glycosylated hemoglobin, and erythrocyte 2,3-diphosphoglycerate concentration.
Brunetti P; Massi-Benedetti M; Puxeddu A; Santeusanio F; Calabrese G; Bolli G; Scionti L; Angeletti G
Horm Metab Res Suppl; 1979; (8):81-6. PubMed ID: 395095
[TBL] [Abstract][Full Text] [Related]
10. Influence of continuous physiologic hyperinsulinemia on glucose kinetics and counterregulatory hormones in normal and diabetic humans.
Saccà L; Sherwin R; Hendler R; Felig P
J Clin Invest; 1979 May; 63(5):849-57. PubMed ID: 447832
[TBL] [Abstract][Full Text] [Related]
11. Influence of insulin infusion kinetics of an artificial beta cell on blood glucose control in insulin-dependent diabetics.
Kerner W; Beischer W; Maier V; Pfeiffer EF
Horm Metab Res Suppl; 1979; (8):71-80. PubMed ID: 395094
[TBL] [Abstract][Full Text] [Related]
12. Comparison of a perfusion syringe (Mill Hill Infusor) and a glucose-controlled insulin infusion system in the regulation of diabetes mellitus.
Stavljenić A; Granić M; Topić B; Skrabalo Z
Horm Metab Res Suppl; 1979; (8):207-11. PubMed ID: 395083
[TBL] [Abstract][Full Text] [Related]
13. The artificial beta cell (Biostator) in the adjustment of instable diabetics--results after 20 months.
Beyer J; Wolf E; Cordes U; Hassingen W
Horm Metab Res Suppl; 1979; (8):127-31. PubMed ID: 395068
[TBL] [Abstract][Full Text] [Related]
14. Continuous intravenous insulin therapy with a miniaturized open-loop system.
Renner R; Hepp KD; Mehnert H; Franetzki M
Horm Metab Res Suppl; 1979; (8):186-90. PubMed ID: 395077
[TBL] [Abstract][Full Text] [Related]
15. Use of glucose-controlled insulin infusion system for improvement of subcutaneous insulin regimen.
Irsigler K; Kritz H; Kaspar L; Brändle J; Franetzki M
Horm Metab Res Suppl; 1979; (8):134-40. PubMed ID: 395070
[TBL] [Abstract][Full Text] [Related]
16. The antidiabetic action of somatostatin-28 as assessed by the artificial endocrine pancreas: greater potency than somatostatin-14.
Hadjidakis DI; Raptis SA; Raptis AE; Karaiskos C; Souvatzoglou A; Diamantopoulos EJ
Horm Metab Res; 1987 Nov; 19(11):574-8. PubMed ID: 2892770
[TBL] [Abstract][Full Text] [Related]
17. Closed-loop system in evaluation of insulin infusion rates for an open-loop system.
Kølendorf K; Christiansen JS; Svendsen PA; Bojsen J
Horm Metab Res Suppl; 1979; (8):205-6. PubMed ID: 395082
[TBL] [Abstract][Full Text] [Related]
18. Dynamic study of the blood viscosity of insulin-dependent diabetics by means of an artificial pancreas.
Drouin P; Rousselle D; Pointel JP; Voisin G; Stoltz JF; Clemens AH; Debry G
Horm Metab Res Suppl; 1979; (8):107-10. PubMed ID: 395064
[TBL] [Abstract][Full Text] [Related]
19. [Effect of biostator control on levels of contra-insulin hormones].
Petkova M; Khristov V; Zlateva S; Tsanev A
Vutr Boles; 1988; 27(3):61-4. PubMed ID: 3206905
[TBL] [Abstract][Full Text] [Related]
20. Blood glucose monitoring and computer regulation by means of an artificial endocrine pancreas.
Kruse-Jarres JD; Braun G; Naegele R; Bresch M; Lehmann U
Horm Metab Res Suppl; 1979; (8):42-5. PubMed ID: 395088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
